Back to Search
GABRIELLE SWARTZ, DO
DO
Student in an Organized Health Care Education/Training Program
NPI: 1770384786Individual
Specialties, Licenses & Credentials
Student in an Organized Health Care Education/Training ProgramPrimary
Student in an Organized Health Care Education/Training Program
Code: 390200000X
Research & Publications (9)
Significant antitumor activity in vivo following treatment with the microtubule agent ENMD-1198.
PMID 18566218·Mol Cancer Ther·2008
7-preclinical
2-methoxyestradiol inhibits hypoxia-inducible factor 1alpha, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squamous cell carcinoma.
PMID 15623651·Clin Cancer Res·2004
4-observational
Identification and characterization of a very low density lipoprotein receptor-binding peptide from tissue factor pathway inhibitor that has antitumor and antiangiogenic activity.
PMID 14739228·Blood·2004
7-preclinical
Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism.
PMID 12782609·Cancer Res·2003
7-preclinical
2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF.
PMID 12726862·Cancer Cell·2003
7-preclinical
2-methoxyestradiol up-regulates death receptor 5 and induces apoptosis through activation of the extrinsic pathway.
PMID 12543804·Cancer Res·2003
7-preclinical
Metastatin: a hyaluronan-binding complex from cartilage that inhibits tumor growth.
PMID 11221828·Cancer Res·2001
7-preclinical
2-Methoxyestradiol: an endogenous antiangiogenic and antiproliferative drug candidate.
PMID 11191057·Cancer Metastasis Rev·2000
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 2401 W BELVEDERE AVE
BALTIMORE, MD 21215 - Phone
- (814) 381-4149
Quick Facts
- NPI
- 1770384786
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 9
Are you this provider?
Claim Your Profile